Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size, Status and Forecast 2024-2031

Report ID: 934686 | Published Date: Jan 2025 | No. of Page: 117 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Sildenafil
        1.2.3 Tadalafil
        1.2.4 Avanafil
        1.2.5 Vardenafil
    1.3 Market by Application
        1.3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital
        1.3.3 Retail Pharmacy
        1.3.4 Online Pharmacies
        1.3.5 Other
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Perspective (2016-2027)
    2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Growth Trends by Regions
        2.2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Share by Regions (2016-2021)
        2.2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2022-2027)
    2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Industry Dynamic
        2.3.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Trends
        2.3.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Drivers
        2.3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Challenges
        2.3.4 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue
        3.1.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue (2016-2021)
        3.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Players (2016-2021)
    3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue
    3.4 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio
        3.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2020
    3.5 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players Head office and Area Served
    3.6 Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service
    3.7 Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Phosphodiesterase Type 5 (PDE5) Inhibitor Breakdown Data by Type
    4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Type (2016-2021)
    4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Type (2022-2027)

5 Phosphodiesterase Type 5 (PDE5) Inhibitor Breakdown Data by Application
    5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Application (2016-2021)
    5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
    6.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
        6.2.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
        6.2.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
        6.2.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
    6.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
        6.3.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
        6.3.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
        6.3.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
    6.4 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country
        6.4.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021)
        6.4.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
    7.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
        7.2.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
        7.2.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
        7.2.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
    7.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
        7.3.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
        7.3.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
        7.3.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
    7.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country
        7.4.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021)
        7.4.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
    8.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
        8.2.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
    8.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
        8.3.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
    8.4 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region
        8.4.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
    9.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
        9.2.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
        9.2.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
        9.2.3 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
    9.3 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
        9.3.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
        9.3.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
        9.3.3 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
    9.4 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country
        9.4.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021)
        9.4.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
    10.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
        10.2.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
    10.3 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
        10.3.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
    10.4 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country
        10.4.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Eli Lilly
        11.1.1 Eli Lilly Company Details
        11.1.2 Eli Lilly Business Overview
        11.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.1.4 Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.1.5 Eli Lilly Recent Development
    11.2 Pfizer
        11.2.1 Pfizer Company Details
        11.2.2 Pfizer Business Overview
        11.2.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.2.4 Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.2.5 Pfizer Recent Development
    11.3 Bayer
        11.3.1 Bayer Company Details
        11.3.2 Bayer Business Overview
        11.3.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.3.4 Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.3.5 Bayer Recent Development
    11.4 Novartis AG
        11.4.1 Novartis AG Company Details
        11.4.2 Novartis AG Business Overview
        11.4.3 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.4.4 Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.4.5 Novartis AG Recent Development
    11.5 Merck
        11.5.1 Merck Company Details
        11.5.2 Merck Business Overview
        11.5.3 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.5.4 Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.5.5 Merck Recent Development
    11.6 GlaxoSmithKline plc
        11.6.1 GlaxoSmithKline plc Company Details
        11.6.2 GlaxoSmithKline plc Business Overview
        11.6.3 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.6.4 GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.6.5 GlaxoSmithKline plc Recent Development
    11.7 Roche
        11.7.1 Roche Company Details
        11.7.2 Roche Business Overview
        11.7.3 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.7.4 Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.7.5 Roche Recent Development
    11.8 AstraZeneca
        11.8.1 AstraZeneca Company Details
        11.8.2 AstraZeneca Business Overview
        11.8.3 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.8.4 AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.8.5 AstraZeneca Recent Development
    11.9 BaiYunShan General Factory
        11.9.1 BaiYunShan General Factory Company Details
        11.9.2 BaiYunShan General Factory Business Overview
        11.9.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.9.4 BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.9.5 BaiYunShan General Factory Recent Development
    11.10 SK Chemicals
        11.10.1 SK Chemicals Company Details
        11.10.2 SK Chemicals Business Overview
        11.10.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.10.4 SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.10.5 SK Chemicals Recent Development
    11.11 Teva Pharma
        11.11.1 Teva Pharma Company Details
        11.11.2 Teva Pharma Business Overview
        11.11.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.11.4 Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.11.5 Teva Pharma Recent Development
    11.12 Dong-A ST
        11.12.1 Dong-A ST Company Details
        11.12.2 Dong-A ST Business Overview
        11.12.3 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.12.4 Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.12.5 Dong-A ST Recent Development
    11.13 Metuchen Pharma
        11.13.1 Metuchen Pharma Company Details
        11.13.2 Metuchen Pharma Business Overview
        11.13.3 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.13.4 Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.13.5 Metuchen Pharma Recent Development
    11.14 Seoul Pharma
        11.14.1 Seoul Pharma Company Details
        11.14.2 Seoul Pharma Business Overview
        11.14.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.14.4 Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.14.5 Seoul Pharma Recent Development
    11.15 Vectura Group
        11.15.1 Vectura Group Company Details
        11.15.2 Vectura Group Business Overview
        11.15.3 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
        11.15.4 Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
        11.15.5 Vectura Group Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Sildenafil
    Table 3. Key Players of Tadalafil
    Table 4. Key Players of Avanafil
    Table 5. Key Players of Vardenafil
    Table 6. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2016-2021)
    Table 10. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2022-2027)
    Table 12. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Trends
    Table 13. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Drivers
    Table 14. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Challenges
    Table 15. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Restraints
    Table 16. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Players (2016-2021)
    Table 18. Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor as of 2020)
    Table 19. Ranking of Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service
    Table 23. Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2016-2021)
    Table 27. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Application (2016-2021)
    Table 31. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021) & (US$ Million) 
    Table 38. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027) & (US$ Million) 
    Table 39. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2016-2021) & (US$ Million) 
    Table 50. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2022-2027) & (US$ Million) 
    Table 51. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021) & (US$ Million) 
    Table 56. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027) & (US$ Million) 
    Table 57. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. Eli Lilly Company Details
    Table 64. Eli Lilly Business Overview
    Table 65. Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 66. Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 67. Eli Lilly Recent Development
    Table 68. Pfizer Company Details
    Table 69. Pfizer Business Overview
    Table 70. Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 71. Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 72. Pfizer Recent Development
    Table 73. Bayer Company Details
    Table 74. Bayer Business Overview
    Table 75. Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 76. Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 77. Bayer Recent Development
    Table 78. Novartis AG Company Details
    Table 79. Novartis AG Business Overview
    Table 80. Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 81. Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 82. Novartis AG Recent Development
    Table 83. Merck Company Details
    Table 84. Merck Business Overview
    Table 85. Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 86. Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 87. Merck Recent Development
    Table 88. GlaxoSmithKline plc Company Details
    Table 89. GlaxoSmithKline plc Business Overview
    Table 90. GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 91. GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 92. GlaxoSmithKline plc Recent Development
    Table 93. Roche Company Details
    Table 94. Roche Business Overview
    Table 95. Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 96. Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 97. Roche Recent Development
    Table 98. AstraZeneca Company Details
    Table 99. AstraZeneca Business Overview
    Table 100. AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 101. AstraZeneca Recent Development
    Table 102. BaiYunShan General Factory Company Details
    Table 103. BaiYunShan General Factory Business Overview
    Table 104. BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 105. BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 106. BaiYunShan General Factory Recent Development
    Table 107. SK Chemicals Company Details
    Table 108. SK Chemicals Business Overview
    Table 109. SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 110. SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 111. SK Chemicals Recent Development
    Table 112. Teva Pharma Company Details
    Table 113. Teva Pharma Business Overview
    Table 114. Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 115. Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 116. Teva Pharma Recent Development
    Table 117. Dong-A ST Company Details
    Table 118. Dong-A ST Business Overview
    Table 119. Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 120. Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 121. Dong-A ST Recent Development
    Table 122. Metuchen Pharma Company Details
    Table 123. Metuchen Pharma Business Overview
    Table 124. Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 125. Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 126. Metuchen Pharma Recent Development
    Table 127. Seoul Pharma Company Details
    Table 128. Seoul Pharma Business Overview
    Table 129. Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 130. Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 131. Seoul Pharma Recent Development
    Table 132. Vectura Group Company Details
    Table 133. Vectura Group Business Overview
    Table 134. Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Product
    Table 135. Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
    Table 136. Vectura Group Recent Development
    Table 137. Research Programs/Design for This Report
    Table 138. Key Data Information from Secondary Sources
    Table 139. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type: 2020 VS 2027
    Figure 2. Sildenafil Features
    Figure 3. Tadalafil Features
    Figure 4. Avanafil Features
    Figure 5. Vardenafil Features
    Figure 6. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2020 VS 2027
    Figure 7. Hospital Case Studies
    Figure 8. Retail Pharmacy Case Studies
    Figure 9. Online Pharmacies Case Studies
    Figure 10. Other Case Studies
    Figure 11. Phosphodiesterase Type 5 (PDE5) Inhibitor Report Years Considered
    Figure 12. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 13. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 14. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions: 2020 VS 2027
    Figure 15. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2022-2027)
    Figure 16. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Players in 2020
    Figure 17. Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor as of 2020
    Figure 18. The Top 10 and 5 Players Market Share by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2020
    Figure 19. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2016-2021)
    Figure 20. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2022-2027)
    Figure 21. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
    Figure 23. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
    Figure 24. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Country (2016-2027)
    Figure 25. United States Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Canada Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
    Figure 29. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
    Figure 30. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Country (2016-2027)
    Figure 31. Germany Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. France Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. U.K. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Italy Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Russia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Nordic Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
    Figure 39. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
    Figure 40. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Region (2016-2027)
    Figure 41. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. South Korea Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Australia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
    Figure 49. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
    Figure 50. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Country (2016-2027)
    Figure 51. Mexico Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Brazil Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
    Figure 55. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
    Figure 56. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Country (2016-2027)
    Figure 57. Turkey Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Saudi Arabia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. UAE Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Eli Lilly Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 61. Pfizer Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 62. Bayer Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 63. Novartis AG Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 64. Merck Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 65. GlaxoSmithKline plc Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 66. Roche Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 67. AstraZeneca Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 68. BaiYunShan General Factory Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 69. SK Chemicals Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 70. Teva Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 71. Dong-A ST Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 72. Metuchen Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 73. Seoul Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 74. Vectura Group Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
    Figure 75. Bottom-up and Top-down Approaches for This Report
    Figure 76. Data Triangulation
    Figure 77. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group
Frequently Asked Questions
Phosphodiesterase Type 5 (PDE5) Inhibitor report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Phosphodiesterase Type 5 (PDE5) Inhibitor report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Phosphodiesterase Type 5 (PDE5) Inhibitor report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Digital Railway

In order to improve the efficiency of existing infrastructure, digital railways are provided with ... Read More

Pet Care Service

Pet care service is for dogs, cats, birds, fish and other pets to provide a full range of profess ... Read More